Heparin-induced Thrombocytopenia Market Size

Heparin-induced Thrombocytopenia Market size is expected to reach USD 63 billion by the end of 2036, growing at a CAGR of 5% during the projected period i.e., 2024-2036. In the year 2023, the industry size of heparin-induced thrombocytopenia was over USD 10 billion.

Heparin Induced thrombocytopenia may be a driving cause of horribleness and mortality in hospitalized patients, happening as an after-effect of life and limb-threatening thrombosis. In a least 5% of patients getting heparin, this condition is watched, as there are signs of a diminish in the number of platelets by more than 50 % encouraging the arrangement of blood clots. Consequently, it is becoming profoundly vital to treat this condition, clearing the way for a have of treatment approaches. 

Heparin is widely used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increases the risk of heparin-induced thrombocytopenia.